Hepatitis C Virus Recurrence After Liver Transplantation: Analysis of Factors Related to Sustained Viral Response
✍ Scribed by M. Jiménez-Pérez; A.B. Sáez-Gómez; J.A. Pérez-Daga; J.M. Lozano-Rey; J. de la Cruz-Lombardo; J.M. Rodrigo-López
- Book ID
- 116936012
- Publisher
- Elsevier Science
- Year
- 2010
- Tongue
- English
- Weight
- 118 KB
- Volume
- 42
- Category
- Article
- ISSN
- 0041-1345
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Recurrent hepatitis C infection is an important cause of progressive fibrosis, cirrhosis, and graft loss following orthotopic liver transplantation. Treatment for posttransplant recurrence of hepatitis C with interferon-based therapy is difficult but results in loss of detectable virus in up to 30%
## Background: The value of immunohistochemical methods to identify hepatitis C virus antigen (HCVAg) in liver tissue has not been established. We have evaluated the significance of HCVAg expression in livers of patients with transplants and recurrent hepatitis C virus (HCV) infection. Methods: Fo
Factors associated with sustained virological response (SVR) in patients treated for hepatitis C virus (HCV) recurrence after liver transplantation (LT) are unclear. Ninety-nine HCV-positive/hepatitis B surface antigen-negative patients received antiviral treatment (AVT) with interferon/peginterfero
This study aimed to investigate the factors associated with viral breakthrough among liver transplant recipients who receive lamivudine monoprophylaxis. Consecutive patients receiving liver transplantation for HBV-related liver disease from June 1999 to October 2000 were studied. All patients receiv
Sustained virologic response (SVR) after antiviral therapy for recurrent hepatitis C virus (HCV) infection in liver transplant (LT) recipients is consistently lower than that achieved in non-LT patients. We evaluated efficacy and safety of pegylated interferon (IFN) and ribavirin (RBV) therapy in LT